July 28, 2017July 28, 2017

Ofev Improves Microvascular Architecture in Mouse Model of Lung Fibrosis

Ofev (nintedanib) improved microvascular architecture in a mouse model of lung fibrosis, uncovering a potential new mode of action through which the therapy works to treat idiopathic pulmonary fibrosis (IPF). The study ... Read more

November 2, 2015November 2, 2015

Results in Fruquintinib Proof-of-Concept Phase II Clinical Trial for Non-Squamous NSCLC Show Promise

Lung Cancer, News

Pharmaceutical company Hutchison China MediTech Limited (Chi-Med) recently announced that its R&D drug subsidiary Hutchison MediPharma Limited (HMP) will receive a $10 million dollar milestone payment from its partner Eli Lilly and Company ... Read more